Schwab Charles Investment Management Inc. Has $45 Million Holdings in Hologic, Inc. (HOLX)

Schwab Charles Investment Management Inc. raised its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 3.8% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,052,523 shares of the medical equipment provider’s stock after acquiring an additional 38,522 shares during the period. Schwab Charles Investment Management Inc.’s holdings in Hologic were worth $44,996,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of HOLX. Grove Bank & Trust raised its stake in Hologic by 115.8% during the 3rd quarter. Grove Bank & Trust now owns 2,860 shares of the medical equipment provider’s stock valued at $105,000 after acquiring an additional 1,535 shares during the last quarter. Hall Laurie J Trustee raised its stake in Hologic by 10.2% during the 2nd quarter. Hall Laurie J Trustee now owns 2,425 shares of the medical equipment provider’s stock valued at $110,000 after acquiring an additional 225 shares during the last quarter. MPS Loria Financial Planners LLC purchased a new stake in Hologic during the 2nd quarter valued at approximately $191,000. National Asset Management Inc. purchased a new stake in Hologic during the 2nd quarter valued at approximately $203,000. Finally, Rothschild Investment Corp IL purchased a new stake in Hologic during the 3rd quarter valued at approximately $236,000. 92.77% of the stock is owned by hedge funds and other institutional investors.

HOLX has been the subject of several analyst reports. Bank of America raised Hologic from a “neutral” rating to a “buy” rating and set a $50.00 price objective for the company in a research note on Thursday, January 4th. Goldman Sachs Group upgraded Hologic from a “buy” rating to a “conviction-buy” rating and boosted their target price for the stock from $45.00 to $50.00 in a research report on Friday, December 8th. Needham & Company LLC reiterated a “buy” rating and set a $48.00 target price (up previously from $46.00) on shares of Hologic in a research report on Tuesday, December 5th. Cowen upgraded Hologic to a “buy” rating and set a $52.00 target price on the stock in a research report on Wednesday, December 20th. Finally, Zacks Investment Research cut Hologic from a “hold” rating to a “sell” rating in a research report on Tuesday, October 17th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Hologic has a consensus rating of “Buy” and an average target price of $48.79.

Hologic, Inc. (HOLX) opened at $40.45 on Thursday. The stock has a market capitalization of $11,676.25, a P/E ratio of 20.00, a price-to-earnings-growth ratio of 1.89 and a beta of 0.77. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.61 and a current ratio of 0.79. Hologic, Inc. has a 52-week low of $35.76 and a 52-week high of $46.80.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Wednesday, November 8th. The medical equipment provider reported $0.50 earnings per share for the quarter, topping analysts’ consensus estimates of $0.49 by $0.01. The business had revenue of $802.90 million for the quarter, compared to analysts’ expectations of $792.54 million. Hologic had a return on equity of 21.69% and a net margin of 24.70%. The company’s revenue was up 10.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.52 EPS. sell-side analysts forecast that Hologic, Inc. will post 2.18 earnings per share for the current fiscal year.

In related news, Director Elaine Ullian sold 9,282 shares of the company’s stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $40.50, for a total value of $375,921.00. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Karleen Marie Oberton sold 1,023 shares of the company’s stock in a transaction that occurred on Monday, November 20th. The stock was sold at an average price of $39.84, for a total value of $40,756.32. The disclosure for this sale can be found here. Corporate insiders own 0.79% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Schwab Charles Investment Management Inc. Has $45 Million Holdings in Hologic, Inc. (HOLX)” was first posted by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The legal version of this piece of content can be viewed at https://sportsperspectives.com/2018/02/08/schwab-charles-investment-management-inc-has-45-million-holdings-in-hologic-inc-holx.html.

Hologic Profile

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply